Lyell Immunopharma, Inc.
Clinical trials sponsored by Lyell Immunopharma, Inc., explained in plain language.
-
First-in-Human trial tests engineered immune cells against Tough-to-Treat colon cancer
Disease control Recruiting nowThis is an early-stage safety study testing a new type of personalized cell therapy called GCC19CART for adults with metastatic colorectal cancer that has come back or stopped responding to standard treatments. The study aims to find a safe dose and see how well the body tolerate…
Phase: PHASE1 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Apr 01, 2026 22:56 UTC
-
New Two-Pronged cancer therapy aims to outsmart relapsed lymphoma
Disease control Recruiting nowThis study is testing a new, experimental CAR T-cell therapy called ronde-cel against currently approved CAR T-cell therapies for patients with aggressive large B-cell lymphoma that has returned or not responded to initial chemotherapy. The new therapy is designed to target two m…
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New 'Double-Target' cell therapy fights Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing a new, experimental cell therapy called LYL314 for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The therapy, a type of CAR-T, is designed to attack cancer cells by targeting two markers (CD19 …
Phase: PHASE1, PHASE2 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC